Trial Profile
Interleukin-2, interferon alpha, capecitabine and vinblastin for treatment of metastatic renal cell carcinoma: a multicenter study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Interferon alpha (Primary) ; Interleukin-2 (Primary) ; Vinblastine (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 02 Nov 2005 New trial record.